利培酮联合丁螺环酮对首发精神分裂症患者临床疗效及安全性的影响

Effect of Risperidone Combined with Buspirone on Clinical Efficacy and Safety in Patients with First-episode Schizophrenia

目的:探究利培酮、丁螺环酮联合应用于首发精神分裂症中的临床价值。方法:选取2021年2月—2023年9月石河子绿洲医院精神科二科收治的70例首发精神分裂症患者为研究对象,按照随机数字表法分为对照组(接受利培酮单一治疗)、研究组(在对照组的基础上联合丁螺环酮治疗),各35例。对比两组疗效、临床症状程度、脂代谢指标及不良反应。结果:研究组总有效率(97.14%)高于对照组(77.14%),差异有统计学意义(χ^(2)=6.248,P=0.012);治疗前,两组临床症状程度比较,差异均无统计学意义(P>0.05);治疗后,研究组的临床症状程度均低于对照组,差异均有统计学意义(P<0.05);两组治疗前、治疗后甘油三酯、总胆固醇比较,差异均无统计学意义(P>0.05);研究组不良反应率(11.43%)与对照组(17.14%)比较,差异无统计学意义(χ^(2)=2.540,P=0.111)。结论:利培酮联合丁螺环酮有利于提高临床首发精神分裂症患者的治疗效果,减轻临床症状程度,且具有一定的安全性,不会引起脂代谢异常。

Objective:To explore the clinical value of Risperidone combined with Buspirone on clinical efficacy and safety in patients with first-episode schizophrenia.Method:A total of 70 patients with first-stage schizophrenia admitted to Department of PsychiatryⅡ,Oasis Hospital,Shihezi from February 2021 to September 2023 were selected as the study objects,and they were divided into the control group(received Risperidone monotherapy)and the study group(combined with Buspirone therapy on the basis of the control group)according to random number table method,with 35 cases in each group.The efficacy,degree of clinical symptoms,lipid metabolism indexes and adverse reactions were compared between the two groups.Result:The total effective rate of the study group(97.14%)was higher than that of the control group(77.14%),the difference was statistically significant(χ^(2)=6.248,P=0.012).Before treatment,there were no significant differences in the degree of clinical symptoms between the two groups(P>0.05).After treatment,the degree of clinical symptoms in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in triglyceride and total cholesterol between the two groups before and after treatment(P>0.05).There was no significant difference in the adverse reaction rate between the study group(11.43%)and the control group(17.14%)(χ^(2)=2.540,P=0.111).Conclusion:Risperidone combined with Buspirone can improve the therapeutic effect of patients with first-episode schizophrenia,reduce the degree of clinical symptoms,and has a certain safety,without causing abnormal lipid metabolism.